Free Trial

The Great Abiomed (NASDAQ: ABMD) Comeback Continues

The Great Abiomed (NASDAQ: ABMD) Comeback Continues
Back at the start of May, we wrote about how shares of Abiomed (NASDAQ: ABMD) were working hard to prove the bears wrong and to break a two-year downtrend. In the eleven weeks since then, they’ve tacked on an impressive 55%, are firmly above their pre-COVID levels and show no signs of slowing down.

That puts them a full 130% higher than their March lows and into the upper bracket of top-performing stocks in the post coronavirus landscape. The company’s banner product, or rather family of products, is Impella, various versions of a tiny heart pump that offer blood flow support to patients. With the onset of COVID, all non-essential treatment was canceled as part of the effort to slow the spread of the virus and to free up medical resources to focus on coronavirus patients instead. The standard Impella user was told to hold tight and make do until COVID was under control.

Abiomed Doomsday Scenario Avoided

Abiomed’s revenue’s dependence on Impella made it particularly vulnerable to the worst-case scenarios that were being drawn up and imagined in the early days of the pandemic. With non-COVID patients basically being turned away from hospitals, where was the company going to generate revenue? This attitude helps to explain the 40% drop in a single month that shares experienced through March. However, as the infamous curve has been flattened in many countries and economies have started to reopen, the doomsday scenarios have not come to pass.

Downward pressure on the shares has been lifted as a result and the subsequent uplift has been supported by the company’s recent acquisition of Breethe. This Maryland health startup manufactures a kind of artificial lung which assists patients whose own lungs are struggling with the likes of coronavirus. Being able to staple a revenue-generating product that’s in hot demand into their portfolio has been a winning move by management.

Wall Street will be watching their upcoming earnings report closely to see just how well Impella’s revenue has bounced back and how strong the Breethe business line has been performing. Recent updates from the FDA have been promising and are no doubt adding to the general hype.

Last week, they approved digital data streaming from an Impella device to a central server where artificial intelligence can go to work on behalf of doctors. In June, the FDA gave the nod on the first-in-human study of one of the Impella heart pumps in high-risk percutaneous coronary intervention patients. That same week, another version of the pump was approved for emergency use for the treatment of hospitalized COVID patients who were experiencing heart failure.

Abiomed Looking Ahead

If the narrative after the company’s last earnings report was that COVID hadn’t hurt the company’s revenues as much as expected, the narrative going into the next is sure how much did COVID benefit them. Their addressable market has increased, their exposure to COVID-19 has turned into a net positive and investors are expecting them to continue to make hay while the sun shines.

Even with RSI around 75, it’s hard to say that shares are looking stretched at current levels. They’re just starting to reverse a downtrend that took 75% off their value from September 2018 through March 2020, so there’s plenty of catchup to be done yet. They’ve a solid uptrend supporting the current run that interested investors can use to time entry or plan an exit.

Depending on what comes out in the next earnings report, due in a fortnight, we could well be writing another piece entitled “The Great Abiomed Comeback Is Complete” in the near future.

The Great Abiomed (NASDAQ: ABMD) Comeback Continues

Where should you invest $1,000 right now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report
Sam Quirke
About The Author

Sam Quirke

Contributing Author

Technical Analysis

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Abiomed (ABMD)
2.6097 of 5 stars
$381.02flatN/A65.47N/A
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Alphabet Gaining Momentum: Can It Reach $200 by December?

Alphabet Gaining Momentum: Can It Reach $200 by December?

Alphabet (GOOGL) is in the midst of a year-end rally, climbing 10% since September, and some analysts predict it could gain another 30% by Christmas!

Recent Videos

ISRG Stock Surges: AI and Healthcare Innovation at the Core
Energy Vault’s 100% Stock Jump: CEO Discusses $350M Project in Australia in MarketBeat CEO Series
Market Shifts After Election: What Stocks Could Benefit Most?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines